Atypicality of clozapine

Package insert. Clozaril (clozapine). East Hanover, NJ: Sandoz Pharmaceuticals, 1991.

Safferman A Lieberman JA Kane JM Szymanski S Kinon B . Update on the clinical efficacy and side effects of clozapine. Schizophr Bull 1991; 17: 247–61.

Meltzer HY Bastani B Kwon KY Ramirez LF Burnett S Sharpe J . A prospective study of clozapine in treatment-resistant schizophrenic patients. 1. A preliminary report. Psychopharmacology 1989; 99: S68–S72.

Leadbetter R Shutty M Pavalonis D Vieweg V Higgins P Downs M . Clozapine-induced weight gain: prevalence and clinical relevance. Am J Psychiatry 1992; 149: 68–72.

Lamberti JS Bellnier T Schwarzkopf SB . Weight gain among schizophrenic patients treated with clozapine. Am J Psych 1992; 149: 689–90.

Ereshefsky L Watanabe MD Tran-Johnson TK . Clozapine: an atypical antipsychotic agent. Clin Pharm 1989; 8: 691–709.

Clozaril systems data. Clozaril treatment trends (the Clozaril treatment systems newsletter), East Hanover, NJ: Sandoz Pharmaceuticals 1992; 1 spring:2.

Pelonero AL Elliott RL . Ethical and clinical considerations in selecting who will receive clozapine. Hasp Community Psychiatry 1990; 41: 878–82.

Fitton A Heel RC . Clozapine: a review of its pharmacologic properties, and therapeutic use in schizophrenia. Drugs 1990; 40: 722–47.